Patents Assigned to APICORE US LLC
-
Publication number: 20200347013Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: July 15, 2020Publication date: November 5, 2020Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10752580Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2, 5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: GrantFiled: November 2, 2017Date of Patent: August 25, 2020Assignee: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10626086Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: GrantFiled: March 22, 2019Date of Patent: April 21, 2020Assignee: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10590071Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: GrantFiled: October 25, 2018Date of Patent: March 17, 2020Assignee: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10519121Abstract: Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.Type: GrantFiled: December 26, 2017Date of Patent: December 31, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Rao Kannapan, Ananda Babu Thirunavakarasu, Veerabhadra Rao Bobbili, Gaurav Yadav
-
Patent number: 10508080Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2, 5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: GrantFiled: February 1, 2019Date of Patent: December 17, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10464888Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: GrantFiled: February 1, 2019Date of Patent: November 5, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10442832Abstract: Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including the novel polymorph H are disclosed.Type: GrantFiled: February 2, 2016Date of Patent: October 15, 2019Assignee: APICORE US LLCInventors: Ravishanker Kovi, Ashish Naik, Piyush Fadadu, Jayaraman Kannapan
-
Patent number: 10392417Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.Type: GrantFiled: October 30, 2017Date of Patent: August 27, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
-
Publication number: 20190218177Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: March 22, 2019Publication date: July 18, 2019Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Publication number: 20190177269Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2, 5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: February 1, 2019Publication date: June 13, 2019Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Publication number: 20190169119Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2, 5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: February 1, 2019Publication date: June 6, 2019Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Patent number: 10221184Abstract: Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.Type: GrantFiled: January 4, 2018Date of Patent: March 5, 2019Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Gaurav Yadav, Veerabhadra Rao Bobbili, Shivnath Sahebrao Patil, Sanjay F. Thakor
-
Publication number: 20190062268Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: October 25, 2018Publication date: February 28, 2019Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Publication number: 20190002421Abstract: Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.Type: ApplicationFiled: December 26, 2017Publication date: January 3, 2019Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Rao Kannapan, Ananda Babu Thirunavakarasu, Veerabhadra Rao Bobbili, Gaurav Yadav
-
Publication number: 20180208599Abstract: Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 1; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7,15.2, 15.8, 16.4 23.1, 25.0, 27.8±0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG. 3; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.Type: ApplicationFiled: January 4, 2018Publication date: July 26, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Gaurav Yadav, Veerabhadra Rao Bobbili, Shivnath Sahebrao Patil, Sanjay F. Thakor
-
Patent number: 9988389Abstract: Methods are disclosed for making 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 10, 2016Date of Patent: June 5, 2018Assignee: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Sanjay F. Thakor, Ashish Naik, Dhakhada Chetana Bharatbhai, Khichi Kuldip Fatehlal, Shivnath Sahebrao Patil
-
Publication number: 20180127452Abstract: Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10° C. to about 90° C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.±0.2 degrees 2-theta.Type: ApplicationFiled: October 30, 2017Publication date: May 10, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Ananda Babu Thirunavakarasu, Piyush D. Fadadu, Piyush B. Thumar
-
Publication number: 20180057454Abstract: Isosulfan blue and processes for the preparation thereof are provided. A process is also provided for preparation of the intermediate, 2-chlorobenzaldehyde-5-sulfonic acid, sodium salt of formula (2), used in the preparation thereof and a procedure for the isolation of benzaldehyde-2,5-disulfonic acid, di-sodium salt of the formula (3). Also provided is a process for the preparation of an isoleuco acid of formula (4), which upon oxidation gives rise to isosulfan blue of pharmaceutical grade which can be used for preparation of pharmaceutical formulations. The isolation and purification procedures provided in the process provide substantially pure isosulfan blue with HPLC purity 99.5% or greater.Type: ApplicationFiled: November 2, 2017Publication date: March 1, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Satyam Nampalli, Peter Xavier Tharial
-
Publication number: 20180037606Abstract: Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed.Type: ApplicationFiled: October 17, 2017Publication date: February 8, 2018Applicant: Apicore US LLCInventors: Ravishanker Kovi, Jayaraman Kannapan, Vasanthakumar G. Ramu, Alaparthi Lakshmi Prasad, Talluri Bhushaiah Chowdary, Gaurav Kulkarni, Saiyed Akeel Ahmed Shakeel Ahmed, Veerabhadra Rao Bobbili, N V Raghavalu Dusanapudi, Anand V. Mantri